Abstract 【Objective】 To investigate the relationship between the stability of coronary plaque and the level of platelet chemokines in patients with coronary heart disease (CHD). 【Methods】 From June 2020 to February 2022, 60 CHD patients (observation group) admitted to the 986 Hospital of the Air Force of the People's Liberation Army of China were selected. At the same time, according to the stability of coronary plaque, they were further divided into stable group (n=35) and unstable group (n=25). In addition, 60 healthy volunteers who were healthy during the same period were selected as the study subjects (control group). Platelet chemokine 16 (CXCL16), platelet chemokine 4 (CXCL4), platelet lymphocyte ratio (PLR) and Fractalkine were compared between the observation group and the control group. CXCL16, CXCL4, PLR, Fractalkine indexes of patients with different plaque stability in the observation group were compared. The receiver operating characteristic curve (ROC curve) was used to evaluate the efficacy of CXCL16, CXCL4, PLR, Fractalkine in predicting plaque instability in CHD patients.【Results】 The levels of CXCL16, CXCL4, PLR and Fractalkine in the observation group were significantly higher than those in the control group (P<0.05). The levels of CXCL16, CXCL4, PLR and Fractalkine in the unstable group were higher than those in the stable group (P<0.05). ROC curve analysis shows that the best cut-off values of CXCL16, CXCL4, PLR and Fractalkine for predicting plaque instability were 2.766 μg/L, 0.956 ng/mL, 111.820, 61.064 ng/mL respectively. The area under the CXCL16 curve was 0.975, with high sensitivity and specificity, 0.920 and 0.943 respectively. 【Conclusion】 The levels of CXCL16, CXCL4, PLR and Fractalkine are closely related to the stability of coronary plaque in CHD patients, which is helpful for doctors and nurses to identify the stability of coronary plaque in CHD patients.
WANG Hai-qiang,WANG Lei. Relationship between Coronary Plaque Stability and Platelet Chemokines in Patients with Coronary Heart Disease[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(9): 1329-1331.
2022, Vol. 39 
